Editorial
2017; Elsevier BV; Volume: 106; Issue: 3 Linguagem: Inglês
10.1016/j.xphs.2017.01.010
ISSN1520-6017
Autores Tópico(s)Biomedical Ethics and Regulation
ResumoIn 2014, we appointed 236 academic and industrial scientists, who are all experts in their respective areas of research, as Scientific Advisors to the Editors (SAEs) of the Journal of Pharmaceutical Sciences (JPharmSci®). The primary responsibility of these SAEs was to evaluate the significance and originality of the scientific content of articles submitted to JPharmSci®. Because the terms of these SAEs expired on December 31, 2016, the journal's editorial team, which consists of the editor-in-chief and the twelve editors, recently conducted an analysis of the areas of scientific expertise of these SAEs as well as their employment and geographic demographics. This analysis was conducted in an effort to insure that the group of SAEs appointed on January 1, 2017, adequately covered all of the scientific areas encompassed by the scope of JPharmSci® and that the employment and geographic demographics of this new group of SAEs reflected the employment and geographic demographics of the authors and readers of the journal. I am very pleased to announce here that 152 of the original SAEs were reappointments for new 3-year terms starting on January 1, 2017. These reappointed SAEs include the following individuals: Ilgaz Akseli, Celgene; Kenneth Alexander, Pharm Services and Technologies; Sreedhara Alavattam, Genentech, Inc.; Catherine Amiel, University Paris Est Creteil; Leah Appel, Green Ridge Consulting; Robert Arnold, Auburn University; Mayssa Attar, Allergan, Plc; Kunal Bakshi, GlaxoSmithKline; Sunny Bhardwaj, Merck & Co. Inc.; Jeffrey Blue, Merck & Co. Inc.; Prudence Bradley, Merck & Co., Inc.; Vera Brinks, ProQR Therapeutics; Nicole Buist, Merck & Co., Inc.; Ting Cai, China Pharmaceutical University; Shawn Cao, Amgen, Inc.; Wenjin, Cao, Amgen, Inc.; Stephen Carl, Bristol-Myers Squibb; Louise Carson, Queen's University Belfast; Keith Chadwick, Purdue University; Sayantan Chattoraj, GlaxoSmithKline; Xin Chen, GlaxoSmithKline; Yite Chou, Merck & Co., Inc.; Kwok Chow, Covar Pharmaceuticals Inc.; John Chung, Amgen, Inc.; Maria Jose Cocero Alonso, Valladolid University; Nunzio Denora, University of Bari “Aldo Moro”; Xia Dong, Eli Lilly and Company; Daryl Drummond, Merrimack; Carsten Ehrhardt, Trinity College Dublin; David Engers, SSCI (Division of Albany Molecular Research, Inc.); Yushi Feng, US Food and Drug Administration; Vito Fodera, University of Copenhagen; Nikoletta Fotaki, University of Bath; Marian Gindy, Merck & Co., Inc.; Yuchuan Gong, Abbvie, Inc.; Eric Gorman, Gilead Sciences; Monica Goss, Amgen, Inc.; Francesca Greco, University of Reading; Manish Gupta, GlaxoSmithKline; Karen Hapgood, Monash University; Andrea Hawe, Coriolis Pharma; Hisamitsu Hayashi, University of Tokyo; Xiaorong He, Boehringer-Ingelheim Pharmaceuticals, Inc.; Jeffrey Hemenway, Gilead Sciences; John Higgins, Merck & Co., Inc.; Geoffrey Hird, Liquidia Technologies; Akihiro Hisaka, Chiba University; Stephen Hoag, University of Maryland; Andrew Ingham, Corillonite, Ltd.; Shingo Ito, Kumamoto University; Yijia Jiang, Coherus BioSciences; Liang Jin, Monash University; Janan Jona, Genentech, Inc.; Mouhannad Jumma, Mashriq Pharma; Toshiya Katsura, Ritsumeikan University; Umesh Kestur, Bristol-Myers Squibb; Dae-Duk Kim, Seol National University; Daniel Kirby, Aston University; Sandra Klein, Ernst Moritz Arndt University Greifswald; Klaus Knop, Heinrich Heine University; Mary E. Krause, Bristol-Myers Squibb; Joseph Kushner IV, Pfizer, Inc.; Elizabeth Kwong, Kwong Eureka Solutions; Wooin Lee, Seoul National University; Yung-Chi Lee, Merck & Co., Inc.; Dennis Leung, Genentech, Inc., Jane Z. Li, Boehringer-Ingelheim Pharmaceuticals, Inc.; Xiangmin Liao, Novartis; Sreenivas Reddy Lingireddy, Eli Lilly and Company; Sachin Lohani, Janssen Pharmaceuticals; Enxian Lu, Aucta Pharmaceuticals, LLC.; Qun Lu, Celgene; Denny Mahlin, Uppsala University; Chen Mao, Genentech, Inc.; William Marinaro, Merck & Co. Inc.; Ivan Marziano, Pfizer, Inc.; Satohiro Masuda, Kyushu University Hospital; Caroline McGregor, Merck & Co. Inc.; Craig McKelvey, Merck & Co., Inc.; Brian Meyer, Merck & Co., Inc.; Jeffrey Millard, Cascadian Therapeutics; Qingxin Mu, University of Washington; Arup Mukkherjee, University of Calcutta; Uwe Munster, Bayer AG; Karthik Nagapudi, Genentech, Inc.; Padma Narayan; Tesaro, Inc.; Srividya Neelakantan, Biogen; Seshadri Neervannan, Allergan, Plc; Tri-Hung Nguyen, Monash Institute of Pharmaceutical Sciences; Defang Ouyang, University of Macau; Gautam Pangu, Merck & Co., Inc.; James Patterson, GlaxoSmithKline; Amrit Paudel, RCPE GmbH; Sathyanarayana Perumalla, Teva Pharmaceuticals; Adam Procopio, Merck & Co., Inc.; Chetan Pujara, Allergan, Plc; Dongmei Qiang, Pfizer, Inc.; Clare Rawlinson-Malone, Bristol-Myers Squibb; Brian Rohrs, Bausch & Lomb; Larry Rosen, VenatoRx Pharmaceuticals, Inc.; Katie Ryan, University of College Cork; Christoph Saal, Merck KGaA; Gregory Sacha, Baxter Healthcare; Hideyuki Saito, Kumamoto University Hospital; Robert Saklatvala, Merck & Co., Inc.; Nazila Salamat-Miller, Shire; Atul Saluja, Sanofi; Tapan Sanghvi, Vertex Pharmaceuticals, Inc.; Jay Schrier, Bioserv Corporation; Anna Schwendeman, University of Michigan; Christian Seiler, ViiV Healthcare; Kia Sepassi, Janssen Pharmaceuticals; Roman Shimanovich, Amgen, Inc.; Chinmay Shukla, US Food and Drug Administration; Dmitri Simberg, University of Colorado; Thakur Raghu Raj Singh, Queen's University Belfast; Andria Skinner, Regeneron Pharmaceuticals, Inc.; William Smith, Merck & Co., Inc.; Phillip Snyder, Vertex Pharmaceuticals, Inc.; Im-Sook Song, Kyungpook National University; Omar Sprockel, Bristol-Myers Squibb; Roman Szucs, Pfizer, Inc.; Tappei Takada, University of Tokyo Hospital; Tomohiro Terada, Shiga University of Medical Sciences Hospital; Marc Tesconi, Pfizer, Inc.; Balakumar Thangaraj, Amgen, Inc.; David Thiriot, Merck & Co., Inc.; Avinash Thombre, Pfizer, Inc.; Colin Thompson, Robert Gordon University; Jay Tibbitts, UCB Biopharma; Patrick Trapa, Pfizer, Inc.; Jared Trefethen, Bayer; Natalie Trevaskis, Monash Institute of Pharmaceutical Sciences; Francesco Trotta, University of Torino; Neil Turnbull, Pfizer, Inc.; Yasuo Uchida, Tohoku University; Sitaram Velaga, Luea University of Technology; Matthias Wacker, Fraunhofer Institute of Molecular Biology and Applied Ecology; Randy Wald, Bend Research; Paul Walsh, Merck & Co., Inc.; John Y. Wang, Genentech, Inc.; Zhe Wang, National Institutes of Health; Ke Wu, Allegan, Plc; Tian Wu, Amgen, Inc.; Long Xu, WuXi Apptec; Qingguo Xu, John Hopkins University School of Medicine; Yan Xu, Janssen Pharmaceuticals; Yoon Yeo, Purdue University; Etsuo Yonemochi, Hoshi University; Li Zhang, Center for Disease Control and Prevention; Junshu Zhao, Bristol-Myers Squibb; and Deliang Zhou, AbbVie Inc. I am also very pleased to announce here the appointment of 12 new SAEs for 3-year terms starting on January 1, 2017. These new SAEs include the following individuals: Emmanuel Akala, Howard University; Akhilesh Bhambhani, Merck & Co., Inc.; Reza Esfandiary, MedImmune; David Fissore, Politecnico di Torino; Sarah Gordon, Boehringer-Ingelheim Pharmaceuticals, Inc.; David Hayes, Boehringer-Ingelheim Pharmaceuticals, Inc.; Rene Holm, Janssen Pharmaceuticals; Kevin S. Li, University of Cincinnati; John S. Philo, Alliance Protein Laboratories; Jurgen Siepmann, University of Lille; Maria Vertzoni, National and Kapodistrian University of Athens; and Baojian Wu, Jinnan University. I would also like to take this opportunity to publicly thank the following individuals who have served as SAEs for the past 2.5 years and who will be stepping down as SAEs effective December 31, 2016: Alejandra Aguzzi, UNC School of Dentistry; Muhammad Arayne, University of Karachi; Raj Badhan, Aston University; Intira Coowanitwong, Crysalis Technologies; Alberto Cuitino, Rutgers University; Weiguo Dai, Johnson & Johnson; Lea Ann Dailey, King's College London; Sean Dalziel, Tobira Therapeutics, Inc.; Anne De Paepe, Pfizer Inc.; Xavier Decleves, Universite Paris Descartes; Kung-I Feng, Merck & Co., Inc.; Duoli Guo, Forest Research Institute; Xiao Hu, Biogen, Inc.; Akash Jian, Cubist Pharmaceuticals; Otilia Koo, Bristol-Myers Squibb; Edmund Kostewicz, Goethe University; Michael Kress, Merck & Co., Inc.; Yitong Liu, US Food and Drug Administration; Stephen Machatha, Synageva Biopharma; Susan Mercer, Lipscomb University; Jeremy Merritt, Eli Lilly and Company; Dinesh Mishra, Eli Lilly and Company; Thomas Raub, Eli Lilly and Company; Holger Roehl, F. Hoffmann-La Roche Ltd.; Oliver Stauch, Genentech, Inc.; Markus Thommes, Technische Universitat Dortmund; Roger Weaver, Pfizer Inc.; Chuan-Yu Wu, University of Surrey; Ping Zhao, US Food and Drug Administration; and Jin Zhou, Boehringer-Ingelheim Pharmaceuticals, Inc. Finally, I am very pleased to announce here that 54 of the original group of SAEs were offered and have accepted 3-year appointments as members of the journal's Editorial Advisory Board (EAB). These individuals include Anjali Agrawal, Celgene; Fernando Alvarez-Nunez, Amgen, Inc.; Guohua An, University of Iowa; Pieter Annaert, Katholieke Universiteit Leuven; Alejandro Ayala, Universidade Federal do Ceara; Jane Bai, US Food and Drug Administration; Arvind Bansal, National Institute of Pharmaceutical Education and Research; Bakul Bhatnagar, Pfizer Inc.; Joshua Boateng, University of Greenwich; Ira S. Buckner, Duquesne University; Bodhisattwa Chaudhuri, University of Connecticut; Xiaodong Chen, Bristol-Myers Squibb; Wei Cheng, University of Michigan; Woei Ping Cheng, University of Hertfordshire; Po-Chiang Chiang, Genentech, Inc.; Rutesh Dave, Long Island University; Vivek Dave, St. John Fisher College; Melgardt De Villiers, University of Wisconsin; Roberto DePaz, MedImmune; James DiNunzio, Merck & Co. Inc.; Christine Dufes, University of Strathclyde; Frank Etzler, Lake Erie College of Osteopathic Medicine; John Gamble, Bristol-Myers Squibb; Sandri Giuseppina, University of Pavia; David Harris, Merck & Co, Inc.; Yan He, Sanofi; Jerry Heng, Imperial College London; Paul W. S. Heng, National University of Singapore; Kazutaka Higaki, Okayama University; Katsuhisa Inoue, Tokyo University of Pharmacy and Life Sciences; Kousei Ito, Chiba University; Iwao Yasunori, University of Shizuoka; Marisa Joubert, Amgen, Inc.; Kaoru Kobayashi, Chiba University; Yoshiyuki Kubo, University of Toyama; Yurong Lai, Bristol-Myers Squibb; Margaret Landis, Pfizer, Inc.; Devalina Law, Abbvie, Inc.; Kazuya Maeda, University of Tokyo; Heidi Mansour, University of Arizona; Danforth Miller, Novartis; Noriko Ogawa, Aichi Gakuin University; Satoshi Ohtake, Pfizer, Inc.; Tomoyuki Okuda, Meijo University; Takashi Okura, Teikyo University; Roger Rajewski, University of Kansas; Alfred Rumondor, Merck & Co., Inc.; Marco van de Weert, University of Copenhagen; Michiel van Speybroeck, Pharmavize; Desmond Williams, University of South Australia; Fumiyoshi Yamashita, Kyoto University; Mehran Yazdanian, Teva Pharmaceuticals; Ming Zhang, SUNY Buffalo; and Qi Zhou, Purdue University. With these reappointments and new appointment of SAEs, JPharmSci® will have on January 1, 2017, a total of 164 SAEs and 227 EAB members. Finally, I would like to take this opportunity to thank these 391 pharmaceutical scientists for their service to JPharmSci®.
Referência(s)